AngioDynamics, Inc. (ANGO)

NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09

$15.32+0.66%

Close 2026-09-09 · 1-day change

Standing thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Turnaround

Intact: The reason to own it still holds.

The bull case

AngioDynamics aims to grow revenue to about $314 million in FY26. It plans to keep gross margins near 54-55%. The company targets positive free cash flow in FY26. Recent strategic partnerships and earnings beats support recovery.

The bear case

The company is still loss-making with negative EPS guidance near -$0.26 in FY26. Litigation risks and CEO transition add uncertainty. Revenue growth and margin targets are behind schedule so far.

What's priced in

The market expects about 10% revenue growth but also prices in continued losses. Our fair value near $66 suggests moderate upside if turnaround succeeds.

What has to stay true

Achieve positive free cash flow for FY 2026Intact
Cash Flowprimaryfree cash flow > 0 · FY26 (qualitative)
Breaks if: free cash flow remains negative through FY26
Maintain gross margin between 53.5% and 55.5%Intact
Marginprimary53.5% - 55.5% gross margin · FY26 (guidance)
Breaks if: gross margin falls below 53.5% in FY26
Increase net sales to $313.5M - $315.5M for FY 2026Intact
Revenue Growthprimary~$314M total revenue · FY26 (qualitative)
Breaks if: annual revenue falls below $300M in FY26

Source: QuarterlyIQ research model· Written 2026-07-08· Health checked 2026-09-09· Version 1· Status: Intact· Reviewed when the evidence changes

This is not a price target or investment advice.

Current Outlook

Week of Sep 5, 2026

A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.

ANGO's long-term thesis reflects challenges in execution amid a supportive sector backdrop.

What kind of bet this is

This investment represents a turnaround scenario, as ANGO seeks to improve its financial performance after recent struggles. The current thesis state indicates a cautious watch, given the mixed signals from recent results and management priorities.

What's priced into AngioDynamics, Inc. (ANGO)

The market seems to have priced in a level of fragility due to weak execution quality, but this is not fully reflected in the valuation. ANGO appears cheap compared to peers, with an expectations gap indicating that the market anticipates further challenges.

What the fundamentals likely do

Fundamentals are likely to remain weak in the near term, as management is behind on achieving key priorities like positive free cash flow and maintaining gross margins. However, there is some progress in net sales growth, which could provide a slight boost.

What AngioDynamics, Inc. (ANGO) hinges on

The thesis hinges on several factors, including management's ability to meet guidance without cutting it, the overall health of the job market, and the performance of sector leaders that could influence ANGO's momentum. Any significant changes in these areas could impact the outlook.

What changed in the latest read

What changed

The most important moves since the prior daily snapshot.

Short-term · Daily

No material changes since the prior snapshot.

Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis.

as of 2026-09-09

See upcoming information that could change the risk

Review the evidence to watch, what would become a concern, and what would make it less concerning.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.